Masimo Gains CE Mark for AI-Powered Brain Monitor
Irvine, California, August 18, 2026 Masimo has received the CE Mark for its next-generation smartSedLine™ brain function monitor, introducing...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Irvine, California, August 18, 2026 Masimo has received the CE Mark for its next-generation smartSedLine™ brain function monitor, introducing...
SAN RAFAEL, Calif., August 18, 2026 BioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire Alesta Therapeutics,...
